Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 2/20 | 0.49 |
| ▸ | LAP3 | P28838 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17626462 | 0.98 | SRC (0.64) | SRCCYP2C19SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL14975466 | 0.98 | SRC (0.64) | SRCCYP2C19SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL17626586 | 0.98 | SRC (0.64) | SRCCYP2C19SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL2169863 | 0.87 | CYP2C19 (0.69) | SRCCYP2C19SMN1; SMN2KDM4E | |
| SCHEMBL505384 | 0.84 | CYP2C19 (0.50) | SRCCYP2C19SMN1; SMN2L3MBTL1CYP2C9 | |
| SCHEMBL10814636 | 0.81 | CYP2C19 (0.62) | SRCCYP2C19SMN1; SMN2KDM4E | |
| SCHEMBL310184 | 0.80 | SRC (0.58) | SRCL3MBTL1TDP1KDM4EHPGD | |
| SCHEMBL37038 | 0.80 | SRC (0.73) | SRCCYP2C19L3MBTL1TDP1ANPEP | |
| SCHEMBL6686008 | 0.80 | SRC (0.73) | SRCCYP2C19L3MBTL1TDP1ANPEP | |
| SCHEMBL4272051 | 0.80 | SRC (0.73) | SRCCYP2C19L3MBTL1TDP1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744510-B | Alizarin aminophosphonate ester derivatives and synthetic method thereof and application | 广西师范大学 | 2016-08-17 | — | — | CN | claimed |
| EP-0736539-B1 | Mesoporous crystalline acid composition of a diphosphonate-phosphite of a tetravalent metal which can be used as a catalyst | ENITECNOLOGIE SPA (IT) | 2000-12-20 | — | — | EP | claimed |
| US-5892080-A | Mesoporous crystalline acid composition of a diphosphonate-phosphite of a tetravalent metal which can be used as a catalyst | ENIRICERCHE S.P.A. (IT) | 1999-04-06 | — | — | US | claimed |
| EP-0736539-A2 | Mesoporous crystalline acid composition of a diphosphonate-phosphite of a tetravalent metal which can be used as a catalyst | ENIRICERCHE S.p.A. (IT) | 1996-10-09 | — | — | EP | claimed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| CN-117801014-A | Preparation method of chiral alpha-borane phosphate | 福州大学 | 2024-04-02 | — | — | CN | disclosed |
| CN-111057109-B | Benzodioxole derivative with phosphonate and application thereof | 西安近代化学研究所 | 2023-08-11 | — | — | CN | disclosed |
| CN-116082237-A | Nitrogen-containing heterocyclic compound and preparation method thereof | 安徽中医药大学 | 2023-05-09 | — | — | CN | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11174435-B2 | Levoglucosan-based flame retardant compounds | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2021-11-16 | — | — | US | disclosed |
| CN-113264958-A | Process for preparing phosphorus-containing cyanohydrins | 拜耳作物科学股份公司 | 2021-08-17 | — | — | CN | disclosed |
| US-10961265-B2 | Process for preparing phosphorus containing cyanohydrins | BASF SE (DE) | 2021-03-30 | — | — | US | disclosed |
| US-5296496-A | Treating degenerative diseases | STERLING WINTHROP INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5250619-A | Mixing with concentrates containing phosphorus; melting; cooling; granulation; after-condensation in solid phase | BAYER AKTIENGESELLSCHAFT (DE) | 1993-10-05 | — | — | US | disclosed |
| EP-0549073-A1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5187173-A | Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders | STERLING WINTHROP INC. (US) | 1993-02-16 | — | — | US | disclosed |
| EP-0410230-A2 | Process for preparing high molecular weight polyamides | BAYER AG (DE) | 1991-01-30 | — | — | EP | disclosed |
| EP-0245942-A2 | Process for preparing phosphonic acids | E.R. Squibb & Sons, Inc. (US) | 1987-11-19 | — | — | EP | disclosed |
| US-4670193-A | OXIDATION | E. R. SQUIBB & SONS, INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4035442-A | Polyester filaments flame retarded with end-capped poly(m-phenylene cyclohexylphosphonate) | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | SRC 1846/4885CYP2C19 2076/4885SMN1; SMN2 3358/4885 |
| US-10961265-B2 | Process for preparing phosphorus containing cyanohydrins | PGLS, PHPT1, DCPS | SRC 4460/4885CYP2C19 2261/4885SMN1; SMN2 3791/4885 |
| US-11174435-B2 | Levoglucosan-based flame retardant compounds | PGLS, PFKFB3, PFKFB4 | SRC 3592/4885CYP2C19 1796/4885SMN1; SMN2 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.